Stockscreener 앱 받기
37.97
0.76%
-0.28
전일 마감가:
$38.25
열려 있는:
$37.88
하루 거래량:
678.24K
Relative Volume:
0.32
시가총액:
$3.27B
수익:
$170.10M
순이익/손실:
$-239.59M
주가수익비율:
-13.56
EPS:
-2.8
순현금흐름:
$-191.20M
1주 성능:
+0.21%
1개월 성능:
+16.26%
6개월 성능:
-24.62%
1년 성능:
-32.08%
1일 변동 폭
$37.33
$38.49
1주일 범위
$36.06
$39.38
52주 변동 폭
$30.04
$67.88
크리스퍼 테라퓨틱스 Stock (CRSP) Company Profile
명칭
Crispr Therapeutics Ag
전화
(617) 315-4600
주소
BAARERSTRASSE 14, ZUG
CRSP을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CRSP
Crispr Therapeutics Ag
|
37.98 | 3.27B | 170.10M | -239.59M | -191.20M | -2.80 |
|
VRTX
Vertex Pharmaceuticals Inc
|
503.40 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
607.48 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
656.42 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
268.56 | 32.98B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
254.50 | 26.89B | 3.81B | -644.79M | -669.77M | -6.24 |
크리스퍼 테라퓨틱스 Stock (CRSP) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-02-14 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2025-02-12 | 업그레이드 | TD Cowen | Sell → Hold |
| 2025-02-03 | 개시 | H.C. Wainwright | Buy |
| 2024-08-06 | 재확인 | Needham | Buy |
| 2024-08-02 | 개시 | Rodman & Renshaw | Buy |
| 2024-06-28 | 재개 | Guggenheim | Neutral |
| 2024-02-15 | 개시 | Wolfe Research | Peer Perform |
| 2023-12-11 | 다운그레이드 | TD Cowen | Market Perform → Underperform |
| 2023-10-17 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2023-09-27 | 개시 | Mizuho | Buy |
| 2023-08-17 | 업그레이드 | Citigroup | Neutral → Buy |
| 2023-05-30 | 개시 | William Blair | Outperform |
| 2023-04-13 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-03-21 | 개시 | Bernstein | Mkt Perform |
| 2023-03-17 | 개시 | Bryan Garnier | Buy |
| 2023-03-07 | 개시 | Robert W. Baird | Neutral |
| 2022-10-11 | 개시 | Morgan Stanley | Underweight |
| 2022-08-09 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2022-06-23 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2022-06-17 | 개시 | BMO Capital Markets | Outperform |
| 2022-04-28 | 개시 | Credit Suisse | Neutral |
| 2021-12-07 | 개시 | Cowen | Market Perform |
| 2021-10-19 | 개시 | SVB Leerink | Outperform |
| 2021-06-14 | 업그레이드 | Citigroup | Sell → Neutral |
| 2021-04-21 | 업그레이드 | Jefferies | Hold → Buy |
| 2021-03-04 | 개시 | JMP Securities | Mkt Outperform |
| 2020-12-10 | 재확인 | Chardan Capital Markets | Buy |
| 2020-12-10 | 다운그레이드 | Jefferies | Buy → Hold |
| 2020-12-10 | 재확인 | Needham | Buy |
| 2020-12-07 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2020-10-23 | 개시 | RBC Capital Mkts | Sector Perform |
| 2020-10-05 | 개시 | BofA Securities | Buy |
| 2020-07-28 | 재확인 | Needham | Buy |
| 2020-07-14 | 개시 | SunTrust | Buy |
| 2020-06-15 | 재확인 | Canaccord Genuity | Buy |
| 2020-03-05 | 개시 | Stifel | Hold |
| 2020-02-03 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2019-11-19 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2019-11-12 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2019-08-01 | 개시 | Jefferies | Buy |
| 2019-07-26 | 개시 | Canaccord Genuity | Buy |
| 2019-06-10 | 개시 | ROTH Capital | Buy |
| 2019-04-12 | 개시 | Evercore ISI | Outperform |
| 2019-03-14 | 개시 | William Blair | Mkt Perform |
| 2019-01-28 | 다운그레이드 | Goldman | Buy → Neutral |
| 2019-01-22 | 다운그레이드 | Citigroup | Neutral → Sell |
모두보기
크리스퍼 테라퓨틱스 주식(CRSP)의 최신 뉴스
CRISPR Therapeutics And Intellia Therapeutics: Balancing Market Uncertainty Against Pipeline Catalysts - Seeking Alpha
Genome Engineering Market Generated Opportunities, Future - openPR.com
Susquehanna Fundamental Investments LLC Makes New Investment in CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat
CRISPR Therapeutics AG (NASDAQ:CRSP) Given Consensus Recommendation of "Hold" by Analysts - MarketBeat
CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know - MSN
Barclays PLC Sells 27,790 Shares of CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat
Raymond James Financial Inc. Acquires New Stake in CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat
CRISPR Therapeutics AG (CRSP) Advances But Underperforms Market: Key Facts - MSN
2 Beaten-Down Stocks With Incredible Upside Potential - Yahoo Finance
T. Rowe Price Investment Management Inc. Raises Stake in CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat
XTX Topco Ltd Has $351,000 Stock Holdings in CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat
Legal & General Group Plc Decreases Stock Position in CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat
CRISPR Therapeutics to Report Q1 Earnings: What's in the Cards? - MSN
CRISPR Therapeutics AG (CRSP) Stock Falls Amid Market Uptick: What Investors Need to Know - MSN
Crispr Therapeutics Benefits From Diverse Gene Editing Portfolio; Positive Long-Term Outlook - Morningstar
Prediction: 1 Biotech Stock That Could Surpass Pfizer by 2030 - 24/7 Wall St.
Capital International Sarl Has $7.36 Million Holdings in CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat
Wells Fargo & Company MN Has $8.66 Million Stock Holdings in CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat
Leerink Partnrs Issues Negative Estimate for CRSP Earnings - MarketBeat
‘Incoming Regulatory Tailwinds’ to Spur 90% Upside for CRISPR Therapeutics Stock, Says BMO Capital - Yahoo Finance
Jump Financial LLC Increases Stock Position in CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat
Advisory Services Network LLC Reduces Position in CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat
Crispr Therapeutics AG: Promising Growth with Casgevy Launch and Innovative Pipeline - TipRanks
CRISPR Therapeutics AG (CRSP) Is a Trending Stock: Facts to Know Before Betting on It - MSN
Geode Capital Management LLC Has $39.41 Million Stock Position in CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat
Capital International Investors Grows Position in CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat
5 Monster Stocks -- Such as Coupang -- to Hold for the Next 10 Years - The Motley Fool
CRISPR Therapeutics (NASDAQ:CRSP) Shares Down 4%Should You Sell? - MarketBeat
CRISPR Therapeutics AG (NASDAQ:CRSP) Shares Sold by Reynders McVeigh Capital Management LLC - MarketBeat
CRISPR Therapeutics stock pops following disclosure of RFK Jr. investment - MSN
CRISPR Therapeutics AG (CRSP) Stock Slides as Market Rises: Facts to Know Before You Trade - MSN
BofA Adjusts Price Target on CRISPR Therapeutics to $80 From $86, Keeps Buy Rating - marketscreener.com
Crispr Therapeutics AG (CRSP) Receives a Buy from Bank of America Securities - The Globe and Mail
크리스퍼 테라퓨틱스 (CRSP) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.28%
0.47%
자본화:
|
볼륨(24시간):